Emerging Cancer Immunotherapies: Cutting-Edge Advances and Innovations in Development

Round 1

Reviewer 1 Report

Comments and Suggestions for Authors

The manuscript is a comprehensive review on novel immunotherapies in treating cancer disease. 

Comments:

1. Cancer is a very heterogenous disease, including many malignant diseases. In addition, every form of cancer display a heterogenous pattern of various diseases. The manuscript has not focused on one or a specific number of cancer forms, however, given the topic, lymphoma and leukemia are dominant in the supplementary Tables. I would recommend to consider to focus on novel immunotherapies in these cancer forms, or at least, increase the clinical connection in the text, since the topic "clinical implication" is somewhat abscent in the text. This will make the review more interesting and useful for readers. 

2. The manuscript is very comprehensive. I would however recommend to shorten it significantly and focus on the most important aspects along with conclusions given the findings in the literature. 

3. It is somewhat unclear why some tables are made as supplementary and some not. I would recommend a consistensy - and put all tables in  the supplementary. In addition, Figure 1 and 2 are very illustrative. There are two figures named "Figure 3". The second one summarized the tables (found in the supplementary) well, but must be re-named. 

4. The title should be adjusted to better describe the topic of the review ("immunotherapies" rather than just "treatment" and "therapies"). 

Comments on the Quality of English Language

Final proofreading is recommended to improve formatting and naming of figures

Author Response

The manuscript is a comprehensive review on novel immunotherapies in treating cancer disease. 

We thank the reviewer for their valuable comments and the time dedicated to revising our manuscript.

Comments:

Q1. Cancer is a very heterogenous disease, including many malignant diseases. In addition, every form of cancer display a heterogenous pattern of various diseases. The manuscript has not focused on one or a specific number of cancer forms, however, given the topic, lymphoma and leukemia are dominant in the supplementary Tables. I would recommend to consider to focus on novel immunotherapies in these cancer forms, or at least, increase the clinical connection in the text, since the topic "clinical implication" is somewhat abscent in the text. This will make the review more interesting and useful for readers. 

A1. The aim of this review is to provide an overview of the various approaches used in immunotherapy, without focusing on specific tumour types. In this updated version, we have integrated section 2.6 into section 2.1 to enhance the consistency of the clinical application discussion. Additionally, to better align with the field of immunotherapy, we have removed the section on polyphenol therapy (previously section 2.5).

2. The manuscript is very comprehensive. I would however recommend to shorten it significantly and focus on the most important aspects along with conclusions given the findings in the literature. 

A2. We removed the chapter on polyphenol therapy (chapter 2.5) and incorporated chapter 2.6 into chapters 2 and 2.1.

3. It is somewhat unclear why some tables are made as supplementary and some not. I would recommend a consistensy - and put all tables in  the supplementary. In addition, Figure 1 and 2 are very illustrative. There are two figures named "Figure 3". The second one summarized the tables (found in the supplementary) well, but must be re-named. 

A3. All the tables have now been included in the supplementary material. We apologize for the typographical error in naming the figures; the numbers and references in the text have been corrected.

4. The title should be adjusted to better describe the topic of the review ("immunotherapies" rather than just "treatment" and "therapies"). 

A4. We have modified the title according to your suggestion.

Reviewer 2 Report

Comments and Suggestions for Authors

This is an interesting state-of-the art review covering several recent developments in anticancer immune therapies. The review is scientifically sound and well balanced for the different approaches. The review is well structured except the position of the chapter 2.6 cell therapy clinical trials which should be moved to an earlier place, such as 2.1, but definitely before 2.3.

The manuscript can be recommended for publication after corrected positioning of the 2.6. chapter

Author Response

This is an interesting state-of-the art review covering several recent developments in anticancer immune therapies. The review is scientifically sound and well balanced for the different approaches. The review is well structured except the position of the chapter 2.6 cell therapy clinical trials which should be moved to an earlier place, such as 2.1, but definitely before 2.3.

The manuscript can be recommended for publication after corrected positioning of the 2.6. chapter

We thank the reviewer for their valuable comments and the time dedicated to revising our manuscript. In this new version, as per your suggestion, we have positioned chapter 2.6 within chapters 2 and 2.1.